Results 221 to 230 of about 21,757 (265)

Efficacy of a trivalent Haemophilus paragallinarum vaccine compared to bivalent vaccines

Veterinary Microbiology, 1992
The efficacy of a trivalent oil-adjuvant Coryza vaccine containing serotypes A, B and C of Haemophilus paragallinarum has been compared with that of a bivalent oil-adjuvant Coryza vaccine containing serotypes A and C and that of a commercially available, bivalent A1(OH)3-potentiated vaccine, containing types A and C.
A A, Jacobs, W, Cuenen, P K, Storm
openaire   +2 more sources

Third Vaccine for Haemophilus influenzae?

JAMA: The Journal of the American Medical Association, 1991
THE WAY has been opened to license a third vaccine againstHaemophilus influenzaefor use in 2-month-old infants. Pasteur Merieux, Swiftwater, Pa, the manufacturer of the third vaccine, was in the midst of two double-blind, placebo-controlled studies a year ago when the Food and Drug Administration (FDA) licensed a vaccine againstH influenzaeto Lederle ...
openaire   +1 more source

A Vaccine for Nontypable Haemophilus influenzae

2003
Nontypable H. influenzae (NTHI) is a common commensal of the upper respiratory tract residing in both the nasopharynx and the posterior oropharynx. It is one of the leading causative bacterial pathogens of otitis media (OM) in children and serious urogenital, neonatal and mother-infant infections.
W. Cripps, Allan, M. Kyd, Jennelle
openaire   +1 more source

Developing a nontypeable Haemophilus influenzae (NTHi) vaccine

Vaccine, 2000
There is a current high demand for nontypable Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacteria would preferentially have a tailor-made antigenic ...
Poolman, JT, Bakaletz, L, Cripps, A, Denoel, PA, Forsgren, A, Kyd, J, Lobet, Y   +6 more
openaire   +3 more sources

[Haemophilus influenzae vaccines].

Bulletin de l'Academie nationale de medecine, 1994
The haemophilus vaccines are made of the type b capsular polysaccharide of haemophilus influenzae, polyribosylribitol phosphate (PRP), which is responsive of pathogenic power. However the responsiveness of children to PRP vaccine was found to be very poor in infants.
openaire   +1 more source

Haemophilus influenzae Type b Conjugate Vaccines

1995
In summary, all of the Hib conjugate vaccines are highly immunogenic and efficacious in children older than 12-15 months of age, and HbOC, PRP-OMPC, and PRP-T are highly immunogenic and demonstrated to be efficacious in infants as young as 2 months old.
P J, Kniskern, S, Marburg, R W, Ellis
openaire   +2 more sources

Haemophilus b Conjugate Vaccines

1992
P P, Vella, R W, Ellis
openaire   +2 more sources

Haemophilus influenzae type b vaccination

The Lancet, 1997
A, Melhus, A, Hemansson
openaire   +2 more sources

Vaccination Haemophilus

Journal de Pédiatrie et de Puériculture, 1994
openaire   +1 more source

Haemophilus influenzae b Vaccines

Journal of Tropical Pediatrics, 1994
openaire   +2 more sources